Ernexa Therapeutics (ERNA) Return on Invested Capital (2016 - 2025)
Historic Return on Invested Capital for Ernexa Therapeutics (ERNA) over the last 15 years, with Q3 2025 value amounting to 2.45%.
- Ernexa Therapeutics' Return on Invested Capital fell 32200.0% to 2.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.45%, marking a year-over-year decrease of 32200.0%. This contributed to the annual value of 7.97% for FY2024, which is 53500.0% down from last year.
- Ernexa Therapeutics' Return on Invested Capital amounted to 2.45% in Q3 2025, which was down 32200.0% from 13.92% recorded in Q2 2025.
- In the past 5 years, Ernexa Therapeutics' Return on Invested Capital registered a high of 36.64% during Q1 2024, and its lowest value of 9.73% during Q3 2022.
- Moreover, its 5-year median value for Return on Invested Capital was 2.37% (2021), whereas its average is 1.24%.
- Its Return on Invested Capital has fluctuated over the past 5 years, first skyrocketed by 394600bps in 2024, then plummeted by -307000bps in 2025.
- Quarter analysis of 5 years shows Ernexa Therapeutics' Return on Invested Capital stood at 2.29% in 2021, then fell by -28bps to 2.94% in 2022, then crashed by -148bps to 7.29% in 2023, then skyrocketed by 111bps to 0.81% in 2024, then tumbled by -403bps to 2.45% in 2025.
- Its Return on Invested Capital stands at 2.45% for Q3 2025, versus 13.92% for Q2 2025 and 5.94% for Q1 2025.